Acorda, Amgen and Regeneron Lead Premarket Biotech Movers

Acorda, Amgen and Regeneron Lead Premarket Biotech Movers


Biotech Acorda Therapeutics was soaring ahead of the market open on Thursday, thanks to positive results from a late-stage clinical trial for its inhaled formulation of levodopa, which is used to improve motor function in patients with Parkinson's disease. The company's shares were up 10% in premarket trading, hitting $22.45 apiece on the news.



from Biotech News